Drug Trial Radar · NCT06649812
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Oct 7, 2025
Primary completion
Sep 1, 2028
Study completion Sep 1, 2028
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Oct 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial tests how well venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid® (ViPOR) works in treating patients with CD10 negative diffuse large B-cell lymphoma (DLBCL) and high-grade lymphoma with MYC and BCL2 rearrangements that has come back after a period of improvement (relapsed) and/or that has not responded to previous treatment (refractory). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Ibrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers at abnormal levels. This may help keep cancer cells from growing and spreading. Anti-inflammatory drugs, such as prednisone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Obinutuzumab, a monoclonal antibody, binds to a protein called CD20, which is found on B cells and some types of leukemia and lymphoma cells. Obinutuzumab may block CD20 and help the immune system kill cancer cells. Revlimid, a type of anti-angiogenesis agent and a type of immunomodulating agent, may help the immune system kill abnormal blood cells or cancer cells. It may also prevent the growth of new blood vessels that cancers need to grow. ViPOR may be an effective treatment option for patients with relapsed and/or refractory CD10 negative DLBCL and high-grade B-cell lymphoma with MYC and BCL2 rearrangements.
Conditions
- High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
- Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
- Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
- Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified
- Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
- Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
- Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
- Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified
- Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Interventions
Biopsy ProcedureProcedure
Undergo optional tumor biopsy
Biospecimen CollectionProcedure
Undergo blood sample collection
Bone Marrow AspirationProcedure
Undergo bone marrow aspiration and biopsy
Bone Marrow BiopsyProcedure
Undergo bone marrow aspiration and biopsy
Computed TomographyProcedure
Undergo CT
IbrutinibDrug
Given PO
LenalidomideDrug
Given PO
Magnetic Resonance ImagingProcedure
Undergo MRI
ObinutuzumabBiological
Given IV
Positron Emission TomographyProcedure
Undergo PET
PrednisoneDrug
Given PO
VenetoclaxDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete response (CR) rate (CD10-negative diffuse large B cell lymphoma [DLBCL] and high grade B-cell lymphoma with MYC and BCL2 with or without BCL6 rearrangements [HGBCL-DH-BCL2])Time frame: Up to 5 years
Locations
115 sites in 1 country. Site status is shown where the registry gives one.
Banner University Medical Center - Tucson
Tucson, Arizona · Active not recruiting
University of Arizona Cancer Center-North Campus
Tucson, Arizona · Active not recruiting
Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
Smilow Cancer Hospital-Derby Care Center
Derby, Connecticut · Recruiting
Smilow Cancer Hospital Care Center - Guilford
Guilford, Connecticut · Recruiting
Yale University
New Haven, Connecticut · Recruiting
Kootenai Health - Coeur d'Alene
Coeur d'Alene, Idaho · Recruiting
Kootenai Clinic Cancer Services - Post Falls
Post Falls, Idaho · Recruiting
Kootenai Clinic Cancer Services - Sandpoint
Sandpoint, Idaho · Recruiting
Northwestern University
Chicago, Illinois · Recruiting
Carle at The Riverfront
Danville, Illinois · Suspended
Northwestern Medicine Cancer Center Kishwaukee
DeKalb, Illinois · Recruiting
Carle Physician Group-Effingham
Effingham, Illinois · Suspended
Northwestern Medicine Cancer Center Delnor
Geneva, Illinois · Recruiting
Northwestern Medicine Glenview Outpatient Center
Glenview, Illinois · Recruiting
Northwestern Medicine Grayslake Outpatient Center
Grayslake, Illinois · Recruiting
Northwestern Medicine Lake Forest Hospital
Lake Forest, Illinois · Recruiting
Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois · Suspended
Carle BroMenn Medical Center
Normal, Illinois · Suspended
Carle Cancer Institute Normal
Normal, Illinois · Suspended
Northwestern Medicine Oak Brook
Oak Brook, Illinois · Recruiting
Northwestern Medicine Orland Park
Orland Park, Illinois · Recruiting
Memorial Hospital East
Shiloh, Illinois · Recruiting
Carle Cancer Center
Urbana, Illinois · Suspended
Northwestern Medicine Cancer Center Warrenville
Warrenville, Illinois · Recruiting
Northwest Cancer Center - Crown Point
Crown Point, Indiana · Recruiting
Northwest Oncology LLC
Dyer, Indiana · Recruiting
Saint Mary Medical Center
Hobart, Indiana · Recruiting
Saint Catherine Hospital
Indianapolis, Indiana · Recruiting
The Community Hospital
Munster, Indiana · Recruiting
Women's Diagnostic Center - Munster
Munster, Indiana · Recruiting
Northwest Cancer Center - Valparaiso
Valparaiso, Indiana · Recruiting
Mary Greeley Medical Center
Ames, Iowa · Recruiting
McFarland Clinic - Ames
Ames, Iowa · Recruiting
UI Health Care Mission Cancer and Blood - Ankeny Clinic
Ankeny, Iowa · Recruiting
McFarland Clinic - Boone
Boone, Iowa · Suspended
Saint Anthony Regional Hospital
Carroll, Iowa · Recruiting
Mercy Hospital
Cedar Rapids, Iowa · Recruiting
Oncology Associates at Mercy Medical Center
Cedar Rapids, Iowa · Recruiting
UI Health Care Mission Cancer and Blood - West Des Moines Clinic
Clive, Iowa · Recruiting
Showing 40 of 115 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.